Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. has expanded its financing capacity to support its planned acquisition of OneOncology. The company increased total commitments under its revolving credit facility by $1.0 billion to $5.5 billion, providing additional flexible liquidity.
Cencora also entered into a new senior unsecured term loan agreement totaling $1.5 billion, split into a $500 million tranche maturing two years after draw and a $1.0 billion tranche maturing three years after draw. In addition, the company arranged a separate $3.0 billion 364-day senior unsecured term loan. Proceeds from these loans will help fund the OneOncology purchase price, repay OneOncology’s existing debt, and cover related fees and expenses. Both facilities include leverage covenants generally capped at 4.00 to 1.00, which may temporarily increase to 4.50 to 1.00 when closing a material acquisition, and their funding is conditioned on consummation of the acquisition. These new facilities fully replace previously obtained $4.5 billion bridge financing commitments.
Cencora, Inc. Executive Vice President Silvana Battaglia reported acquiring company shares through an employee stock purchase program. On December 31, 2025, she acquired 27.344 shares of Cencora common stock at a price of $287.088 per share under the Employee Stock Purchase Plan, which is noted as exempt under Rule 16b-3(c) and Rule 16b-3(d). After this purchase, she beneficially owned 18,823.808 shares of common stock in direct ownership.
Cencora, Inc. Executive Vice President Elizabeth S. Campbell reported a small purchase of company common stock. On December 31, 2025, she acquired 33.526 shares of Cencora common stock at a price of $287.088 per share. The filing states this purchase was made through the company’s Employee Stock Purchase Plan under exemptions provided by Rule 16b-3(c) and Rule 16b-3(d). After this transaction, Campbell beneficially owned a total of 23,924.667 shares of Cencora common stock, held in direct ownership.
Cencora, Inc. reported an insider stock sale by an executive vice president on a Form 4. On 12/19/2025, the officer sold 1,677 shares of Cencora common stock at a price of $345 per share, coded as a sale transaction. After this trade, the reporting person beneficially owned 18,796.464 shares of common stock directly. The filing reflects a single non-derivative transaction, with no derivative securities reported.
Cencora, Inc. reported that one of its executive vice presidents, an officer of the company, sold shares of its common stock. On 12/19/2025, the officer disposed of 3,351 shares of Cencora common stock in an open market sale at a price of $342.1 per share. After this transaction, the officer directly beneficially owned 23,891.141 shares of Cencora common stock. This filing reflects a routine insider transaction reported on a Form 4 by a single reporting person.
Cencora, Inc. reported an insider stock transaction by President & CEO and director Robert P. Mauch. On 12/18/2025, he exercised a non-qualified stock option to acquire 3,763 shares of common stock at an exercise price of $86.09 per share, increasing his directly held common stock before the sale to 73,155 shares. On the same date, he reported a sale of 5,096 shares of common stock at a reported price of $343.45 per share. After these transactions, he directly beneficially owned 68,059 shares of Cencora common stock and 7,525 non-qualified stock options. The option exercised was originally scheduled to vest in four equal installments on 11/13/2020, 11/13/2021, 11/13/2022 and 11/13/2023.
Elizabeth Campbell filed a Rule 144 notice to sell 3,351 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 1146377.10, on or about 12/19/2025 on the NYSE. The issuer had 193993444 shares of this class outstanding.
The shares to be sold were acquired from the issuer as compensation via restricted stock vesting on three dates in November 2024: 1,257 shares on 11/08/2024, 1,391 shares on 11/09/2024, and 703 shares on 11/10/2024. Over the past three months, Campbell previously sold 1,886 common shares on 10/01/2025 for gross proceeds of 590846.08.
Cencora, Inc. disclosed that its President & CEO and Director, Robert P. Mauch, made a bona-fide gift of company stock. On 12/17/2025, he transferred 3,000 shares of common stock, coded as a gift, at a reported price of $0 per share, to a charitable donor advised fund. After this transaction, he beneficially owns 66,392 shares of Cencora common stock in direct ownership. The filing is made by a single reporting person and reflects a charitable transfer rather than a market sale or purchase.
Cencora, Inc. disclosed that one of its senior officers reported a stock sale. The reporting person, identified in the signature block as Lazarus Krikorian, who serves as SVP & Chief Accounting Officer, filed a Form 4 as an individual reporting person.
On 12/17/2025, the officer sold 4,031 shares of Cencora common stock at a price of $343.235 per share, coded as a disposition transaction. After this sale, the officer directly beneficially owned 17,154 shares of Cencora common stock. The filing shows the ownership as direct, with no derivative securities reported in the derivative securities table.
Cencora, Inc. reported an insider equity transaction by its Chief Financial Officer, James F. Cleary. On 12/17/2025, he exercised a non-qualified stock option for 45,154 shares of common stock at an exercise price of $86.09 per share. This option, originally vesting in four annual installments beginning in 2020, is now fully exercised with 0 options remaining from that grant.
To cover tax withholding related to the option exercise, 26,952 shares of common stock were disposed of, as noted by the transaction code "F" and the explanation of responses. After these transactions, Cleary directly held 153,143.3479 shares of Cencora common stock.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
